Investigating SGLT2 inhibitors for treating hypertrophic cardiomyopathy
Official title: SGLT-inhibitors in patients with hypertrophic cardiomyopathy
Funded at University of Pennsylvania · NIH-10923375 · Data updated 2026-11-12
This study is looking at whether a diabetes medication called SGLT2 inhibitors can help people with non-obstructive hypertrophic cardiomyopathy (HCM) feel better and improve their heart function, giving them more treatment options for their condition.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | September 1, 2023 |
| Project end | August 31, 2027 |
| Funding year | 2024 |
| Award (this year) | $666,796 |
| NIH project number | 4R33HL164376-02 |
| Project ID | NIH-10923375 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults diagnosed with non-obstructive hypertrophic cardiomyopathy who experience significant symptoms.
✕Less likely to help
Patients with obstructive hypertrophic cardiomyopathy or those without significant symptoms may not benefit from this research.
What this research studies
This research focuses on patients with hypertrophic cardiomyopathy (HCM), particularly those with non-obstructive HCM, who often face severe symptoms and limited treatment options. The study will explore the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i), originally developed for diabetes, to see if they can improve heart function and reduce symptoms in these patients. By assessing the safety and effectiveness of SGLT2i, the research aims to provide new therapeutic options for managing this challenging condition. Patients will be monitored for changes in heart health and overall well-being throughout the study.
Why it matters
Potential benefit: If successful, this research could offer a new treatment option that significantly improves the quality of life for patients with non-obstructive hypertrophic cardiomyopathy.
How similar studies have gone: Previous research has shown promising results for SGLT2 inhibitors in improving cardiovascular outcomes, suggesting potential success for this approach in hypertrophic cardiomyopathy.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Day, Sharlene M — University of Pennsylvania
- Study coordinator: Day, Sharlene M
Related research
Other NIH-funded projects on the same topics.
-
SGLT inhibitors for non-obstructive hypertrophic cardiomyopathy
A testing of a diabetes drug class (SGLT2 inhibitors) to help people with non-obstructive hypertrophic cardiomyopathy feel better and reduce heart-related problems.
-
Using big biobanks to understand rare gene changes in hypertrophic cardiomyopathy
A large study will look at genetic data and health information from many people to better understand how rare gene changes influence hypertrophic cardiomyopathy and its risks.
-
Understanding heart disease in hypertrophic cardiomyopathy through heart tissue and blood analysis
Researchers are studying people with hypertrophic cardiomyopathy to see how genes and signaling in heart tissue and blood relate to disease progression and risk of serious heart problems.
-
Myosin binding protein C variants and heart disease
A doctor-scientist at the University of Michigan is studying how certain genetic changes in a heart protein (MYBPC3) cause hypertrophic cardiomyopathy and whether fixing the protein or its interactions could help people with this condition.
-
MEK inhibitor for severe infantile heart failure in Noonan and related RASopathies
A 12-month, multi-site trial tests whether the medicine trametinib can help infants with life-threatening heart failure due to Noonan syndrome and related genetic conditions.
-
MEK inhibitor shows promise for serious infant heart disease in Noonan/RASopathies
A multi-site study tests whether the drug trametinib can help infants with severe heart muscle thickening caused by Noonan syndrome and related RASopathies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.